ADMA Biologics/$ADMA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ADMA Biologics
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
- Ticker
- $ADMA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 644
- Headquarters
- Ramsey, United States
- Website
- www.admabiologics.com
ADMA Biologics Metrics
BasicAdvanced
$2.9B
17.14
$0.77
0.66
-
Price and volume
Market cap
$2.9B
Beta
0.66
52-week high
$20.46
52-week low
$7.21
Average daily volume
3.7M
Financial strength
Current ratio
6.044
Quick ratio
3.083
Long term debt to equity
0.45
Total debt to equity
0.462
Interest coverage (TTM)
22.04%
Profitability
EBITDA (TTM)
240.702
Gross margin (TTM)
68.53%
Net profit margin (TTM)
35.14%
Operating margin (TTM)
44.93%
Effective tax rate (TTM)
22.23%
Revenue per employee (TTM)
$810,000
Management effectiveness
Return on assets (TTM)
22.41%
Return on equity (TTM)
41.95%
Valuation
Price to earnings (TTM)
17.137
Price to revenue (TTM)
5.89
Price to book
6.71
Price to tangible book (TTM)
6.78
Price to free cash flow (TTM)
23.059
Free cash flow yield (TTM)
4.34%
Free cash flow per share (TTM)
0.573
Growth
Revenue change (TTM)
6.26%
Earnings per share change (TTM)
-9.38%
3-year revenue growth (CAGR)
30.37%
10-year revenue growth (CAGR)
48.66%
3-year earnings per share growth (CAGR)
92.75%
10-year earnings per share growth (CAGR)
-7.58%
What the Analysts think about ADMA Biologics
Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.
Analyst projections of the future price of ADMA Biologics stock.
Bulls say / Bears say
ASCENIV is gaining traction: third-quarter sales rose 31% year on year to $124.7 million and 21% sequentially. New real-world outcomes data in 127 complex patients may help support further adoption. (ADMA Biologics)
Manufacturing yields and a richer ASCENIV mix are improving profitability: gross margin reached 71%, up from 56% a year earlier, while adjusted EBITDA rose 32%. ADMA also raised its minimum adjusted earnings outlook for 2026. (ADMA Biologics)
SG-001 could add a new growth avenue: ADMA says the FDA gave constructive feedback on its proposed clinical plan and assay, and it is preparing an IND submission. The company believes the candidate could eventually generate $300–500 million in annual revenue if approved. (ADMA Biologics)
BIVIGAM remains under pressure from intense competition and pricing: third-quarter revenue fell to $15.4 million from $23.8 million a year earlier and $19.4 million in the prior quarter. That decline offsets some of ASCENIV’s growth. (ADMA Biologics)
A shareholder derivative suit alleges that ADMA inflated revenue by pushing excess ASCENIV inventory on distributors and using extended payment terms. The allegations are untested, but the case creates legal and confidence risks for investors. (InvestmentNews)
SG-001 remains an early-stage, unapproved programme, so it cannot yet offset pressure in marketed products. ADMA is still preparing an IND submission and expects fourth-quarter R&D spending to rise to about $10 million as it makes performance lots. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
ADMA Biologics Financial Performance
Revenues and expenses
ADMA Biologics Earnings Performance
Company profitability
Upcoming events
No upcoming events
ADMA Biologics News
AllArticlesVideos
ADMA Biologics Q3 Earnings Call Highlights
MarketBeat2 days ago
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Newsfile Corp2 months ago
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp2 months ago
Funds containing ADMA Biologics
AllUSDEURGBP
Fund name | Fund size | $ADMA weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.23% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.23% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.23% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.15% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.